Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
| العنوان: | Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK |
|---|---|
| المؤلفون: | P Gunda, A Halliday, Christopher N. Graham, Bruce Kirkham, Will Sullivan, Vanessa Buchanan, LaStella Miles, Steffen M Jugl |
| المصدر: | Pharmacoeconomics |
| بيانات النشر: | Springer International Publishing, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Cost effectiveness, Cost-Benefit Analysis, Drug Resistance, Antibodies, Monoclonal, Humanized, Etanercept, 03 medical and health sciences, Psoriatic arthritis, 0302 clinical medicine, Internal medicine, medicine, Adalimumab, Humans, Original Research Article, health care economics and organizations, 030203 arthritis & rheumatology, Pharmacology, business.industry, 030503 health policy & services, Health Policy, Arthritis, Psoriatic, Public Health, Environmental and Occupational Health, Antibodies, Monoclonal, Middle Aged, medicine.disease, Infliximab, Golimumab, Markov Chains, United Kingdom, Quality-adjusted life year, Clinical Trials, Phase III as Topic, Antirheumatic Agents, Secukinumab, Female, Quality-Adjusted Life Years, 0305 other medical science, business, medicine.drug |
| الوصف: | Objective The aim was to determine the cost effectiveness of secukinumab, a fully human interleukin-17A inhibitor, for adults in the UK with active psoriatic arthritis (PsA) who are tumour necrosis factor inhibitor (TNFi) naïve and without concomitant moderate-to-severe psoriasis, and who have responded inadequately to conventional systemic disease-modifying anti-rheumatic drugs (csDMARDs). Perspective and setting The study took the perspective and setting of the UK National Health Service (NHS). Methods The model structure was a 3-month decision tree leading into a Markov model. Separate analyses based on the number of prior csDMARDs (one and two or more) were conducted, with secukinumab 150 mg compared to standard of care (SoC) and TNFis, respectively, for each subpopulation. Clinical parameters, including response at 3 months, were from the FUTURE 2 trial and a network meta-analysis. Outcomes included total costs and quality-adjusted life years (QALYs) over the 40-year time horizon (3.5% annual discount for both outcomes; cost year 2017), and incremental cost effectiveness ratios (ICERs). Results The ICER for secukinumab 150 mg versus SoC was £28,748 per QALY gained (one prior csDMARD). Secukinumab 150 mg dominated golimumab, certolizumab pegol and etanercept, and had an ICER of £5680 per QALY gained versus adalimumab and > £1 million saved per QALY foregone versus infliximab (two or more prior csDMARDs). Valuing one QALY at between £20,000 and £30,000, the probability of secukinumab having the highest net monetary benefit was 48.9% (one prior csDMARD) and 88.9% (two or more prior csDMARDs). Parameters related to Health Assessment Questionnaire scores were most influential. Conclusions Secukinumab 150 mg at list price appears to represent a cost-effective use of NHS resources for adults with PsA who have responded inadequately to one or two or more prior csDMARDs. Electronic supplementary material The online version of this article (10.1007/s40273-018-0674-x) contains supplementary material, which is available to authorized users. |
| اللغة: | English |
| تدمد: | 1179-2027 1170-7690 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::357f4344ca070dda1960829e993a9172 http://europepmc.org/articles/PMC5999172 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....357f4344ca070dda1960829e993a9172 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 11792027 11707690 |
|---|